Hims Launches Generic Semaglutide in Canada
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 10 hours ago
0mins
Source: stocktwits
- Market Access: Hims has launched generic Semaglutide in Canada at C$149 per month, significantly lower than the C$200-C$400 range for branded Ozempic, which is expected to attract a large number of cost-conscious patients and expand market share.
- Patent Expiration Impact: Novo Nordisk's failure to pay a C$250 patent maintenance fee led to the early expiration of its Semaglutide patent, allowing Hims to quickly enter the competitive GLP-1 market, thereby enhancing its market competitiveness.
- Product Portfolio Expansion: The generic drug offered by Hims is manufactured by Apotex, marking the company's first international rollout, while also providing branded GLP-1 drugs through a partnership with Novo Nordisk, further enriching its product line.
- Intensifying Industry Competition: With Lilly's new drug Retatrutide showing an average weight loss of 28.3% in clinical data, Hims' market strategy will face increased pressure, necessitating continuous innovation to maintain its competitive edge.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy HIMS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on HIMS
Wall Street analysts forecast HIMS stock price to rise
12 Analyst Rating
3 Buy
6 Hold
3 Sell
Hold
Current: 24.010
Low
16.50
Averages
32.95
High
60.00
Current: 24.010
Low
16.50
Averages
32.95
High
60.00
About HIMS
Hims & Hers Health, Inc. provides a consumer-first platform, which helps customers to fulfill their health and wellness needs. Its platform includes access to a provider network, a clinically focused electronic medical record system, digital prescriptions, cloud pharmacy fulfillment, and personalization capabilities. Its digital platform enables access to treatments for a range of chronic conditions, including those related to sexual health, hair loss, dermatology, mental health, and weight loss. It connects patients to licensed healthcare professionals who can prescribe medications when appropriate and prescriptions are fulfilled online through licensed pharmacies on a subscription basis. It also offers access to a range of health and wellness products designed to meet individual needs, which can include curated prescription and non-prescription products. Through its mobile applications, consumers can access a range of educational programs, wellness content, and other services.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Q1 Earnings Overview for Healthcare Tech Stocks
- Hims & Hers Misses Expectations: Hims & Hers Health reported revenues of $608.1 million, a 3.8% year-over-year increase, but fell short of analyst expectations, leading to a 12.9% drop in stock price, indicating market dissatisfaction with its performance.
- Omnicell's Strong Performance: Omnicell achieved revenues of $309.9 million, up 14.9% year-over-year, outperforming analyst expectations by 1.8%, with EBITDA guidance also exceeding forecasts, resulting in a 12.9% stock price increase, reflecting market confidence in its future growth.
- Evolent Health's Mixed Results: Evolent Health reported revenues of $496.2 million, a 2.6% year-over-year increase, but missed analyst expectations, although it beat EPS estimates, leading to a 2.9% stock price increase, suggesting market recognition of its potential.
- Privia Health's Impressive Growth: Privia Health reported revenues of $603.8 million, a 25.8% year-over-year increase, exceeding analyst expectations by 7.4%, despite a 4.3% stock price decline, showcasing its competitive strength among peers.
See More
Hims & Hers Raises $350 Million in Convertible Debt Offering
- Funding Size: Hims & Hers announced a $350 million convertible debt offering aimed at providing capital for long-term growth, but this also increases the risk profile of the business.
- Dilution Risk: The deal includes a capped call mechanism that could limit shareholder dilution; however, if the debt converts to equity, it will still impact existing shareholders.
- Market Confidence Test: The company faces a test of market confidence, needing to demonstrate its growth potential within a limited timeframe to avoid cash flow pressures from debt repayment.
- Strategic Implications: This financing not only provides Hims & Hers with essential capital to support its expansion plans but may also affect its stock price performance, prompting investors to closely monitor subsequent earnings results.
See More
Hims Launches Generic Semaglutide in Canada
- Market Access: Hims has launched generic Semaglutide in Canada at C$149 per month, significantly lower than the C$200-C$400 range for branded Ozempic, which is expected to attract a large number of cost-conscious patients and expand market share.
- Patent Expiration Impact: Novo Nordisk's failure to pay a C$250 patent maintenance fee led to the early expiration of its Semaglutide patent, allowing Hims to quickly enter the competitive GLP-1 market, thereby enhancing its market competitiveness.
- Product Portfolio Expansion: The generic drug offered by Hims is manufactured by Apotex, marking the company's first international rollout, while also providing branded GLP-1 drugs through a partnership with Novo Nordisk, further enriching its product line.
- Intensifying Industry Competition: With Lilly's new drug Retatrutide showing an average weight loss of 28.3% in clinical data, Hims' market strategy will face increased pressure, necessitating continuous innovation to maintain its competitive edge.
See More
Hims & Hers Launches Generic GLP-1 Therapy in Canada
- Generic Launch: Hims & Hers Health has launched a generic version of Novo Nordisk's GLP-1 therapy semaglutide in Canada, marking a significant advancement in personalized treatment plans with a starting price of C$149 per month, which is expected to attract more patients.
- Increased Market Competition: Following Novo Nordisk's loss of Canadian market exclusivity in January, the introduction of generics will allow leading manufacturers like Teva and Sandoz to enter the market, intensifying competition and potentially driving down prices.
- Medical Adaptability: While the generic semaglutide is approved in Canada for type 2 diabetes, healthcare providers can prescribe it off-label for weight management based on clinical judgment, demonstrating the drug's flexibility across different treatment areas.
- Industry Dynamics: India's Dr. Reddy's launched its generic Ozempic in Canada last week, becoming the first G7 nation to approve a knockoff version, further driving market interest and demand for GLP-1 therapies.
See More
Hims & Hers Announces $350 Million Debt Raise
- Debt Financing Amount: Hims & Hers announced a $350 million debt raise, which will fund growth plans but significantly increases business risk.
- Shareholder Dilution Risk: The debt may convert to stock, diluting existing shareholders, or require cash repayment, directly impacting the company's financial health.
- Market Confidence Challenge: The company faces an urgent task to prove to the market that it can become a growth company again, with limited time to do so, which could affect investor confidence and stock performance if unsuccessful.
- Transaction Mechanics Explained: The video elaborates on the mechanics of the debt and capped call transaction, emphasizing the importance of this financing for the company's future development and potential financial challenges.
See More
Trump Delays Military Strike on Iran for Negotiations
- Iran Negotiations Update: Trump announced the delay of a military strike on Iran to allow for 'serious negotiations,' which may ease tensions in the Middle East and positively influence global market sentiment.
- Market Caution: U.S. stock futures were lower on Tuesday, with S&P 500 and Nasdaq futures down 0.3%, reflecting investor caution amid rising inflation concerns ahead of key earnings reports.
- Nvidia Earnings Anticipation: Ahead of its earnings report, Nvidia confirmed early deliveries of its next-generation AI processors to top-tier AI labs, which could drive performance in AI-related stocks.
- Home Depot Price Target Cut: Stifel reduced Home Depot's price target from $375 to $320, indicating potential impacts on investor confidence in the home improvement sector ahead of its earnings report.
See More
Q1 Earnings Overview for Healthcare Tech Stocks
- Hims & Hers Misses Expectations: Hims & Hers Health reported revenues of $608.1 million, a 3.8% year-over-year increase, but fell short of analyst expectations, leading to a 12.9% drop in stock price, indicating market dissatisfaction with its performance.
- Omnicell's Strong Performance: Omnicell achieved revenues of $309.9 million, up 14.9% year-over-year, outperforming analyst expectations by 1.8%, with EBITDA guidance also exceeding forecasts, resulting in a 12.9% stock price increase, reflecting market confidence in its future growth.
- Evolent Health's Mixed Results: Evolent Health reported revenues of $496.2 million, a 2.6% year-over-year increase, but missed analyst expectations, although it beat EPS estimates, leading to a 2.9% stock price increase, suggesting market recognition of its potential.
- Privia Health's Impressive Growth: Privia Health reported revenues of $603.8 million, a 25.8% year-over-year increase, exceeding analyst expectations by 7.4%, despite a 4.3% stock price decline, showcasing its competitive strength among peers.
See More
Hims & Hers Raises $350 Million in Convertible Debt Offering
- Funding Size: Hims & Hers announced a $350 million convertible debt offering aimed at providing capital for long-term growth, but this also increases the risk profile of the business.
- Dilution Risk: The deal includes a capped call mechanism that could limit shareholder dilution; however, if the debt converts to equity, it will still impact existing shareholders.
- Market Confidence Test: The company faces a test of market confidence, needing to demonstrate its growth potential within a limited timeframe to avoid cash flow pressures from debt repayment.
- Strategic Implications: This financing not only provides Hims & Hers with essential capital to support its expansion plans but may also affect its stock price performance, prompting investors to closely monitor subsequent earnings results.
See More
Hims Launches Generic Semaglutide in Canada
- Market Access: Hims has launched generic Semaglutide in Canada at C$149 per month, significantly lower than the C$200-C$400 range for branded Ozempic, which is expected to attract a large number of cost-conscious patients and expand market share.
- Patent Expiration Impact: Novo Nordisk's failure to pay a C$250 patent maintenance fee led to the early expiration of its Semaglutide patent, allowing Hims to quickly enter the competitive GLP-1 market, thereby enhancing its market competitiveness.
- Product Portfolio Expansion: The generic drug offered by Hims is manufactured by Apotex, marking the company's first international rollout, while also providing branded GLP-1 drugs through a partnership with Novo Nordisk, further enriching its product line.
- Intensifying Industry Competition: With Lilly's new drug Retatrutide showing an average weight loss of 28.3% in clinical data, Hims' market strategy will face increased pressure, necessitating continuous innovation to maintain its competitive edge.
See More
Hims & Hers Launches Generic GLP-1 Therapy in Canada
- Generic Launch: Hims & Hers Health has launched a generic version of Novo Nordisk's GLP-1 therapy semaglutide in Canada, marking a significant advancement in personalized treatment plans with a starting price of C$149 per month, which is expected to attract more patients.
- Increased Market Competition: Following Novo Nordisk's loss of Canadian market exclusivity in January, the introduction of generics will allow leading manufacturers like Teva and Sandoz to enter the market, intensifying competition and potentially driving down prices.
- Medical Adaptability: While the generic semaglutide is approved in Canada for type 2 diabetes, healthcare providers can prescribe it off-label for weight management based on clinical judgment, demonstrating the drug's flexibility across different treatment areas.
- Industry Dynamics: India's Dr. Reddy's launched its generic Ozempic in Canada last week, becoming the first G7 nation to approve a knockoff version, further driving market interest and demand for GLP-1 therapies.
See More
Hims & Hers Announces $350 Million Debt Raise
- Debt Financing Amount: Hims & Hers announced a $350 million debt raise, which will fund growth plans but significantly increases business risk.
- Shareholder Dilution Risk: The debt may convert to stock, diluting existing shareholders, or require cash repayment, directly impacting the company's financial health.
- Market Confidence Challenge: The company faces an urgent task to prove to the market that it can become a growth company again, with limited time to do so, which could affect investor confidence and stock performance if unsuccessful.
- Transaction Mechanics Explained: The video elaborates on the mechanics of the debt and capped call transaction, emphasizing the importance of this financing for the company's future development and potential financial challenges.
See More
Trump Delays Military Strike on Iran for Negotiations
- Iran Negotiations Update: Trump announced the delay of a military strike on Iran to allow for 'serious negotiations,' which may ease tensions in the Middle East and positively influence global market sentiment.
- Market Caution: U.S. stock futures were lower on Tuesday, with S&P 500 and Nasdaq futures down 0.3%, reflecting investor caution amid rising inflation concerns ahead of key earnings reports.
- Nvidia Earnings Anticipation: Ahead of its earnings report, Nvidia confirmed early deliveries of its next-generation AI processors to top-tier AI labs, which could drive performance in AI-related stocks.
- Home Depot Price Target Cut: Stifel reduced Home Depot's price target from $375 to $320, indicating potential impacts on investor confidence in the home improvement sector ahead of its earnings report.
See More
